To determine the role of SMYD2 in AKI, we first examined the expression of SMYD2 and its epigenetic marker H3K36me3, and the impact of AZ505, a highly selective inhibitor of SMYD2 in a mouse model of cisplatin-induced AKI. Here, SMYD2 is linked to acute kidney injury.